Pro-oxidant HDL predicts poor outcome in patients with ST-elevation acute coronary syndrome

Summary

Oxidative stress affects clinical outcome in patients with ST-elevation acute coronary syndrome (STE-ACS). Although high-density lipoprotein (HDL) particles are generally considered protective, deleterious properties of HDL have been observed in patients with acute myocardial infarction. Here, we analysed the association between pro oxidant HDL and all-cause mortality in STE-ACS patients. We determined the antioxidant function of HDL in 247 prospectively enrolled patients undergoing primary percutaneous coronary intervention for STE-ACS. Patients were stratified as by a pro-oxidant serum HDL oxidant index (HOI 1) or with an antioxidant serum HOI (HOL< 1) capacity. Multivariate regression analysis was used to relate HOI to survival. The median follow-up time was 23 months (IQR 14.4–40.0 months). Pro-oxidant HDL was observed in 44.1 % of STE-ACS patients and was independently associated with all-cause mortality with a hazard ratio of 3.30(95 %CI 1.50–7.27, p = 0.003). Mortality rates were higher in patients with baseline pro-oxidant HDL compared to patients with preserved HDL function at 30 days (11.9 % vs 2.2 %, p=0.002), and at 4 years (22.9 % vs 8.7 %, p=0.002). Elevated neutrophil counts were a strong and independent predictor for pro-oxidant HDL with an odds ratio per standard deviation of 1.50 (95 %CI 1.11–2.03, p=0.008), as was history of prior acute myocardial infarction, elevated triglycerides levels and reduced glomerular filtration rate. In conclusion, pro-oxidant HDL represents a strong and independent predictor of long-term as well as short-term all-cause mortality in STE-ACS patients. Elevated neutrophil counts predicted the presence of serum pro-oxidant HDL. The maintenance of HDL functions might be a promising therapeutic target in STE-ACS patients.

Keywords

STE-ACS - HDL - antioxidant function - outcome

• References

• 1 Pfeffer MA, Braunwald E. Ventricular remodelling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81: 1161-1172.
• 2 Jaeschke H. et al. Hypoxic damage generates reactive oxygen species in isolated perfused rat liver. Biochem Biophys Res Commun 1988; 150: 568-574.
• 3 Silvestre JS. et al. Post-ischaemic neovascularisation and inflammation. Cardiovasc Res 2008; 78: 242-249.
• 4 Ardlie NG. et al. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 1989; 76: 117-124.
• 5 Hori M, Nishida K. Oxidative stress and left ventricular remodelling after myocardial infarction. Cardiovasc Res 2009; 81: 457-464.
• 6 Stocker R, Keaney JF Jr.. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004; 84: 1381-1478.
• 7 Weidtmann A. et al. Mildly oxidized LDL induces platelet aggregation through activation of phospholipase A2. Arterioscler Thromb Vasc Biol 1995; 15: 1131-1138.
• 8 Wraith KS. et al. Oxidized low-density lipoproteins induce rapid platelet activation and shape change through tyrosine kinase and Rho kinase-signaling pathways. Blood 2013; 122: 580-589.
• 9 Barter PJ. et al. Antiinflammatory properties of HDL. Circ Res 2004; 95: 764-772.
• 10 Navab M. et al. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 2001; 42: 1308-1317.
• 11 Patel PJ. et al. The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol 2011; 58: 2068-2075.
• 12 Patel PJ. et al. Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. Eur J Heart Fail 2013; 15: 1215-1219.
• 13 Holy EW. et al. High-density lipoprotein from patients with coronary heart disease loses anti-thrombotic effects on endothelial cells: impact on arterial thrombus formation. Thromb Haemost 2014; 112: 1024-1035.
• 14 Riwanto M. et al. Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodelling. Circulation 2013; 127: 891-904.
• 15 Morrow DA. et al. TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 2000; 102: 2031-2037.
• 16 Breton CV. et al. HDL anti-oxidant function associates with LDL level in young adults. Atherosclerosis 2014; 232: 165-170.
• 17 Yin F. et al. Diesel exhaust induces systemic lipid peroxidation and development of dysfunctional pro-oxidant and pro-inflammatory high-density lipoprotein. Arterioscler Thromb Vasc Biol 2013; 33: 1153-1161.
• 18 Adlbrecht C. et al. Long-term outcome after thrombectomy in acute myocardial infarction. Eur J Clin Invest 2010; 40: 233-241.
• 19 Burzotta F. et al. Manual thrombus-aspiration improves myocardial reperfusion: the randomized evaluation of the effect of mechanical reduction of distal embolisation by thrombus-aspiration in primary and rescue angioplasty (RE-MEDIA) trial. J Am Coll Cardiol 2005; 46: 371-376.
• 20 Napodano M. et al. Intracoronary thrombectomy improves myocardial reperfusion in patients undergoing direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 2003; 42: 1395-1402.
• 21 Noman A. et al. Impact of thrombus aspiration during primary percutaneous coronary intervention on mortality in ST-segment elevation myocardial infarction. Eur Heart J 2012; 33: 3054-3061.
• 22 Frias MA. et al. HDL protects against ischaemia reperfusion injury by preserving mitochondrial integrity. Atherosclerosis 2013; 228: 110-116.
• 23 Gu SS. et al. The protective effect of ApolipoproteinA-I on myocardial ischaemia-reperfusion injury in rats. Life Sci 2007; 81: 702-709.
• 24 Schwartz GG. et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012; 367: 2089-2099.
• 25 Huang Y. et al. Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex. J Clin Invest 2013; 123: 3815-3828.
• 26 Shah AS. et al. Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J Lipid Res 2013; 54: 2575-2585.
• 27 Alwaili K. et al. The HDL proteome in acute coronary syndromes shifts to an inflammatory profile. Biochim Biophys Acta 2012; 1821: 405-415.
• 28 Shao B. et al. Myeloperoxidase targets apolipoprotein A-I, the major high density lipoprotein protein, for site-specific oxidation in human atherosclerotic lesions. J Biol Chem 2012; 287: 6375-6386.
• 29 Koeffler HP. et al. Myeloperoxidase: its structure and expression during myeloid differentiation. Blood 1985; 65: 484-491.
• 30 Baldus S. et al. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108: 1440-1445.
• 31 Carbone F. et al. Pathophysiological role of neutrophils in acute myocardial infarction. Thromb Haemost 2013; 110: 501-514.
• 32 Distelmaier K. et al. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb Haemost 2009; 102: 564-572.
• 33 Distelmaier K. et al. Prognostic value of culprit site neutrophils in acute coronary syndrome. Eur J Clin Invest 2014; 44: 257-265.
• 34 O’Donoghue M. et al. Association between baseline neutrophil count, clopidogrel therapy, and clinical and angiographic outcomes in patients with ST-elevation myocardial infarction receiving fibrinolytic therapy. Eur Heart J 2008; 29: 984-991.
• 35 Chapman AL. et al. Ceruloplasmin is an endogenous inhibitor of myeloperoxidase. J Biol Chem 2013; 288: 6465-6477.
• 36 Chevrier I. et al. Myeloperoxidase genetic polymorphisms modulate human neutrophil enzyme activity: genetic determinants for atherosclerosis?. Atherosclerosis 2006; 188: 150-154.
• 37 Undurti A. et al. Modification of high density lipoprotein by myeloperoxidase generates a pro-inflammatory particle. J Biol Chem 2009; 284: 30825-30835.
• 38 La Franca E. et al. Relationship between inflammatory markers and new cardiovascular events in patients with acute myocardial infarction who underwent primary angioplasty. Global J Health Sci 2013; 05: 48-54.
• 39 Smolina K. et al. Long-term survival and recurrence after acute myocardial infarction in England, 2004 to 2010. Circulation Cardiovasc Qual Outcomes 2012; 05: 532-540.
• 40 Kennedy DJ. et al. Diminished antioxidant activity of high-density lipoprotein-associated proteins in chronic kidney disease. J Am Heart Assoc 2013; 02: e000104.
• 41 Weichhart T. et al. Serum amyloid A in uremic HDL promotes inflammation. J Am Soc Nephrol 2012; 23: 934-947.
• 42 Dounousi E. et al. Oxidative stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006; 48: 752-760.
• 43 Hansel B. et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004; 89: 4963-4971.
• 44 de Souza JA. et al. Metabolic syndrome features small, apolipoprotein A-I-poor, triglyceride-rich HDL3 particles with defective anti-apoptotic activity. Atherosclerosis 2008; 197: 84-94.
• 45 Ekelof S. et al. Reduced oxidative stress in STEMI patients treated by primary percutaneous coronary intervention and with antioxidant therapy: a systematic review. Cardiovasc Drugs Ther 2014; 28: 173-181.
• 46 Adams V. et al. Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties. Circ Res 2013; 113: 1345-1355.
• 47 Kelesidis T. et al. A biochemical fluorometric method for assessing the oxidative properties of HDL. J Lipid Res 2011; 52: 2341-2351.
• 48 Kelesidis T. et al. Effects of lipid-probe interactions in biochemical fluorometric methods that assess HDL redox activity. Lipids Health Dis 2012; 11: 87.